Labcorp launches companion diagnostic for amgen's newly-approved lung cancer therapy

Burlington, n.c.--(business wire)--labcorp® (nyse: lh), a leading global life sciences company, today announced the availability of therascreen® kras pcr mutation analysis, a companion diagnostic to identify patients with non-small cell lung cancer (nsclc) who are eligible for treatment with lumakras™ (sotorasib), a new treatment option developed by amgen. labcorp's oncology platform brings together the company's leadership in diagnostic testing with its comprehensive drug development services,
LH Ratings Summary
LH Quant Ranking